Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440011 · ClinicalTrials.gov registry record · Phase 4
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
A Phase 4 study of Glaucoma and Ocular Hypertension, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 266
- Enrollment target
- 1
- Study location
NCT00440011 is a Phase 4 study of Glaucoma and Ocular Hypertension that has completed, run by Allergan. The registered enrollment target is 266 participants, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00440011, a Phase 4 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 266 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%
Conditions Studied
Interventions
- DRUG bimatoprost 0.03% eye drops
- DRUG travoprost 0.004% eye drops
Study Locations (1)
California
- - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00440011
The ClinicalTrials.gov registry entry for NCT00440011 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (71% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which bimatoprost 0.03% eye drops is the first listed.
NCT00440011 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00440011 about?
NCT00440011 is a clinical study titled "Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%". Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%
What is the current status of trial NCT00440011?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 266 participants. The study started on 2006-08. Estimated completion is 2007-10.
What conditions does trial NCT00440011 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT00440011?
The interventions under investigation include: bimatoprost 0.03% eye drops (DRUG), travoprost 0.004% eye drops (DRUG).
Who is sponsoring clinical trial NCT00440011?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00440011 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.